

PF 43(5) Table of Contents

Publish date: November 1, 2017

PROPOSED IRA

[Proposed Interim Revision Announcements](#)

USP MONOGRAPHS

[Diclofenac Sodium and Misoprostol Delayed-Release Tablets \(1-Mar-2018\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Salix Species Bark \(1-Mar-2018\)](#)

[Salix Species Bark Dry Extract \(1-Mar-2018\)](#)

[Salix Species Bark Powder \(1-Mar-2018\)](#)

NF MONOGRAPHS

[Diethyl Sebacate \(1-Mar-2018\)](#)

IN-PROCESS REVISION

[In-Process Revision](#)

GENERAL CHAPTERS

[<630> Visual Comparison \[NEW\] \(USP41-NF36 2S\)](#)

[<785> Osmolality and Osmolarity \(USP41-NF36 2S\)](#)

[<855> Nephelometry, Turbidimetry, and Visual Comparison \(USP41-NF36 2S\)](#)

[<857> Ultraviolet-Visible Spectroscopy \(USP41-NF36 2S\)](#)

[<1211> Sterilization and Sterility Assurance of Compendial Articles \(USP41-NF36 2S\)](#)

[<1222> Terminally Sterilized Pharmaceutical Products - Parametric Release \(USP41-NF36 2S\)](#)

[<1228.4> Depyrogenation By Rinsing \[NEW\] \(USP41-NF36 2S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[Aluminum Oxide Strips \[NEW\] \(USP41-NF36 2S\)](#)

[Ammonium Tartrate \[NEW\] \(USP41-NF36 2S\)](#)

[Cellulose Diethylaminoethyl \[NEW\] \(USP41-NF36 2S\)](#)

[Diethyl Phthalate \[NEW\] \(USP41-NF36 2S\)](#)

[Indigo Carmine \(USP41-NF36 2S\)](#)

[Magnesium Carbonate \[NEW\] \(USP41-NF36 2S\)](#)

[p-Nitroaniline \(USP41-NF36 2S\)](#)

[Potassium Pyroantimonate \(USP41-NF36 2S\)](#)

[Sulfiram \[NEW\] \(USP41-NF36 2S\)](#)

[Trimethylamine Hydrochloride \[NEW\] \(USP41-NF36 2S\)](#)

Indicators

[Eriochrome Black T \(USP41-NF36 2S\)](#)

REFERENCE TABLES

Container Specifications

[Container Specifications \[NEW\] \(USP41-NF36 2S\)](#)

Description and Solubility

[Description and Relative Solubility of USP and NF Articles \(USP41-NF36 2S\)](#)

[Description and Solubility - D](#)

[Description and Solubility - G](#)

[Description and Solubility - P](#)

[Description and Solubility - R](#)

USP MONOGRAPHS

[Acarbose Tablets \[NEW\] \(USP41-NF36 2S\)](#)

[Acetaminophen and Codeine Phosphate Tablets \(USP41-NF36 2S\)](#)

[Atropine Sulfate \(USP41-NF36 2S\)](#)

[Azacitidine \[NEW\] \(USP41-NF36 2S\)](#)

[Bacitracin \(USP41-NF36 2S\)](#)

[Betahistine Hydrochloride \(USP41-NF36 2S\)](#)

[Biotin Compounded Oral Suspension \[NEW\] \(USP41-NF36 2S\)](#)

[Chlorothiazide Compounded Oral Suspension \[NEW\] \(USP41-NF36 2S\)](#)

[Cod Liver Oil \(USP41-NF36 2S\)](#)

[Cyclophosphamide Compounded Oral Suspension \[NEW\] \(USP41-NF36 2S\)](#)

[Desvenlafaxine \[NEW\] \(USP41-NF36 2S\)](#)

[Desvenlafaxine Fumarate \[NEW\] \(USP41-NF36 2S\)](#)

[Desvenlafaxine Succinate \[NEW\] \(USP41-NF36 2S\)](#)

[Dextromethorphan \(USP41-NF36 2S\)](#)

[Dextromethorphan Hydrobromide \(USP41-NF36 2S\)](#)

[Dichlorphenamide Tablets \(USP41-NF36 2S\)](#)

[Diphenhydramine Hydrochloride Capsules \(USP41-NF36 2S\)](#)

[Diphenhydramine Hydrochloride Oral Powder \[NEW\] \(USP41-NF36 2S\)](#)

[Diphenhydramine Hydrochloride Oral Solution \(USP41-NF36 2S\)](#)

[Diphenhydramine and Phenylephrine Hydrochlorides Tablets \(USP41-NF36 2S\)](#)

[Ephedrine \(USP41-NF36 2S\)](#)

[Ephedrine Sulfate \(USP41-NF36 2S\)](#)

[Eptacog Alfa Activated \(USP41-NF36 2S\)](#)

[Eptacog Alfa Activated for Injection \(USP41-NF36 2S\)](#)

[Exenatide Injection \[NEW\] \(USP41-NF36 2S\)](#)

[Fludarabine Phosphate \(USP41-NF36 2S\)](#)

[Fludarabine Phosphate \(USP41-NF36 2S\)](#)
[Fluvastatin Sodium \(USP41-NF36 2S\)](#)
[Fosinopril Sodium \(USP41-NF36 2S\)](#)
[Gadobutrol \[NEW\] \(USP41-NF36 2S\)](#)
[Guanabenz Acetate Tablets \(USP41-NF36 2S\)](#)
[Iscotrizinol \[NEW\] \(USP41-NF36 2S\)](#)
[Isotretinoin Capsules \(USP41-NF36 2S\)](#)
[Ivermectin Compounded Oral Solution, Veterinary \[NEW\] \(USP41-NF36 2S\)](#)
[Lansoprazole Delayed-Release Capsules \(USP41-NF36 2S\)](#)
[Leflunomide Compounded Oral Suspension \[NEW\] \(USP41-NF36 2S\)](#)
[Loratadine Orally-Disintegrating Tablets \(USP41-NF36 2S\)](#)
[Mirtazapine Compounded Oral Suspension, Veterinary \[NEW\] \(USP41-NF36 2S\)](#)
[Naproxen Sodium and Pseudoephedrine Hydrochloride Extended-Release Tablets \[NEW\] \(USP41-NF36 2S\)](#)
[Orlistat Capsules \(USP41-NF36 2S\)](#)
[Phenylephrine Hydrochloride Injection \(USP41-NF36 2S\)](#)
[Phenylephrine Hydrochloride Tablets \(USP41-NF36 2S\)](#)
[Phytonadione \(USP41-NF36 2S\)](#)
[Polidocanol \[NEW\] \(USP41-NF36 2S\)](#)
[Prazosin Hydrochloride Capsules \(USP41-NF36 2S\)](#)
[Prazosin Hydrochloride Compounded Oral Suspension \[NEW\] \(USP41-NF36 2S\)](#)
[Propafenone Hydrochloride Tablets \(USP41-NF36 2S\)](#)
[Pseudoephedrine Hydrochloride Tablets \(USP41-NF36 2S\)](#)
[Rotigotine \[NEW\] \(USP41-NF36 2S\)](#)
[Rotigotine Transdermal System \[NEW\] \(USP41-NF36 2S\)](#)
[Scaffold Human Amniotic Membrane Allograft \[NEW\] \(USP41-NF36 2S\)](#)
[Sennosides \(USP41-NF36 2S\)](#)
[Sotalol Hydrochloride \(USP41-NF36 2S\)](#)
[Torsemide Tablets \(USP41-NF36 2S\)](#)
[Triamcinolone Acetonide \(USP41-NF36 2S\)](#)
[Triamcinolone Acetonide Ointment \(USP41-NF36 2S\)](#)
[Urea Compounded Irrigation \[NEW\] \(USP41-NF36 2S\)](#)
[Vigabatrin \(USP41-NF36 2S\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[L-Alpha-Glycerolphosphorylcholine \[NEW\] \(USP41-NF36 2S\)](#)
[Cod Liver Oil Capsules \(USP41-NF36 2S\)](#)
[Dong Quai Root \[NEW\] \(USP41-NF36 2S\)](#)
[Dong Quai Root Powder \[NEW\] \(USP41-NF36 2S\)](#)

NF MONOGRAPHS

[Dextrose Excipient \(USP41-NF36 2S\)](#)
[Fumaric Acid \(USP41-NF36 2S\)](#)
[Maleic Acid \(USP41-NF36 2S\)](#)

STAGE 4 HARMONIZATION

[Stage 4 Harmonization](#)

GENERAL CHAPTERS

[<621> Chromatography \[NEW\] \(USP41-NF36 2S\)](#)

NF MONOGRAPHS

[Sodium Lauryl Sulfate](#)

[Wheat Starch](#)

STIMULI TO THE REVISION PROCESS

[Stimuli to The Revision Process](#)

[Assessment of Drug Product Performance - Bioavailability, Bioequivalence, and Dissolution <1090>:
Status Update](#)

[Considerations for Possible Revision to Align All USP Uniformity Requirements](#)

[Determination of Heat of Fusion of USP Melting Point Standards By Differential Scanning Calorimetry](#)

[Evaluation of Screening Technologies for Assessing Medicines Quality](#)

[The Future of Normality In USP-NF](#)

[The Rationale and Proposed Changes to the Revision of Elastomeric Closures for Injections <381>](#)

[The Development of Compendial Rapid Sterility Tests](#)